New drug review
Emcitate
Review section
| Field | Value |
|---|---|
| Drug | Emcitate (tiratricol) |
| Indication reviewed | MCT8 deficiency |
| Therapeutic category | Thyroid hormone receptor agonists |
| Manufacturer | Egetis Therapeutics |
| Regulatory status | Approved September 28, 2026 |
| Data as of | September 29, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Indications
Table 1. FDA-approved indications
Boxed warning and contraindication
Age range of the indication
Pharmacokinetics
Table 2. Pharmacokinetic parameters
| Generic Name(s) | Bioavailability | Protein Binding | Metabolism | Excretion | Half-Life |
|---|---|---|---|---|---|
| Tiratricol | Not reported | “Tiratricol plasma protein binding is 99%.” | “Tiratricol is metabolized by stepwise deiodination, sulfation and glucuronidation, mainly in the liver.” | “Tiratricol and its metabolites are predominantly eliminated in urine as inorganic iodine and in bile.” | “The steady state half-life is approximately 12 hours for a 70 kg patient and 9.4 hours for a 25 kg patient.” |
Absorption, food effect, distribution, and clearance
Specific populations
Exposure-response and QT interval
Drug interactions
Table 3. Major drug interactions
Abbreviations: BCRP=breast cancer resistance protein; CYP=cytochrome P450; LC-MS/MS=liquid chromatography tandem mass spectrometry; MATE=multidrug and toxin extrusion protein; NDRIs=norepinephrine-dopamine reuptake inhibitors; OAT=organic anion transporter; OATP=organic anion transporting polypeptide; OCT=organic cation transporter; P-gp=P-glycoprotein; PPI=proton pump inhibitor; T3=triiodothyronine; TBG=thyroxine-binding globulin; UGT=uridine diphosphate glucuronosyltransferase
Basis of the interaction statements
Adverse drug events
Lens findings in animals and vision assessment in young children
Pregnancy and lactation
Dosing and administration
Table 5. Usual dosing regimens
See the current prescribing information for full details.
Dosage reduction for new or worsening thyrotoxicosis
Missed dose, vomiting, and discontinuation
Preparation and administration
Storage and split tablets
Effectiveness
Table 6. Comparative clinical trials
Abbreviations: CI=confidence interval; RTP=randomized treatment period; SD=standard deviation; T3=triiodothyronine; ULN=upper limit of normal
Study 2 as published (Triac Trial I): registration and co-primary endpoints, which the prescribing information does not report
“This trial is registered with ClinicalTrials.gov, number NCT02060474.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prespecified primary endpoint was the change in serum T3 concentrations from baseline to month 12. The co-primary endpoints were changes in concentrations of serum thyroid-stimulating hormone (TSH), free and total thyroxine (T4), and total reverse T3 from baseline to month 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serum T3 concentration decreased from 4·97 nmol/L (SD 1·55) at baseline to 1·82 nmol/L (0·69) at month 12 (mean decrease 3·15 nmol/L, 95% CI 2·68-3·62; p<0·0001), while serum TSH concentrations decreased from 2·91 mU/L (SD 1·68) to 1·02 mU/L (1·14; mean decrease 1·89 mU/L, 1·39-2·39; p<0·0001) and serum free T4 concentrations decreased from 9·5 pmol/L (SD 2·5) to 3·4 (1·6; mean decrease 6·1 pmol/L (5·4-6·8; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote